Bridge Report on EIKEN CHEMICAL CO., LTD. Issued: 1H FY3/14 Results and Full FY3/14 Estimates

Investment Bridge, one of Japan's leading IR services companies, has released a
“Bridge Report” on EIKEN CHEMICAL CO., LTD. (TOKYO:  4549) reviewing first
half fiscal year March 2014 earnings results and full fiscal year March 2014
earnings estimates. 
Report Highlights 
* EIKEN CHEMICAL is a general manufacturer of clinical diagnostics, including
immunological and serological, microbiological, clinical chemistry, urine
analysis and molecular genetics. 
* Net sales of the first half of fiscal year (FY) 2014 was 15,000 million yen,
up 2.9% year-on-year. 
* There is no change in the estimates for FY 2014. 
* Overall sales exceeded the sales and profit estimates announced at the
beginning of the fiscal year, and the business performance shows steady
improvement. 
EIKEN CHEMICAL is the major manufacturer of clinical diagnostics.  Its
immunochemical fecal occult blood test reagents occupies over 50% share of the
domestic market.  It is strengthening its molecular genetics.  It is actively
promoting license business. 
About Bridge Report:
Bridge Report is produced by Investment Bridge Co., Ltd. and provides accurate
and objective information about the earnings, business strategies, and other
information of publicly traded Japanese companies. 
Contact:
Investment Bridge Co., Ltd.
mailto:eiken@cyber-ir.co.jp 
Contributed via: Bloomberg Publisher WEB Service 
 
Press spacebar to pause and continue. Press esc to stop.